The global cloud based drug discovery platform market is around usd 4.5 billion by the end of 2027. At cagr 13.5% during 2017-2027 and top key players are ibm corp,accenture plc,bioxcel corporation,cloud pharmaceuticals

Drug discovery platform is a research and development platform where medicines are discovered and are formulated. In recent years, the drug discovery platform is observing great adoption of digital technologies. For instance, some key players are storing large data in cost effective manner in the cloud based drug discovery platforms. This platform enables many customers to overcome different challenges by establishing a network of web and mobile accessible applications. It enables secure and collaborative project management and the capability to share project information.

Request For Free Sample- https://www.kennethresearch.com/sample-request-10076261

Market Size and Forecast

The global cloud based drug discovery platform market was valued around USD 4.5 Billion by the end of 2027. The CAGR of global cloud based drug discovery platform market is around 13.5% during 2017-2027. The increasing market growth can be attributed to increase in the implementation of cloud-based platforms in various application segments. Rise in adoption of cloud based mobile applications for various drug discoveries is also a reason for the expansion of the market size.

The global cloud based drug discovery platform market can be segmented on the basis of type and application. On the basis of application, it is further segmented into pharmaceutical companies, hospitals, biotech vendors and contract research organizations. The pharmaceutical sub-segment is the leading end-user segment in the global cloud based drug discovery platform market. The constant rise in demand of drug from the various pharmaceutical companies is expected to drive the market growth of the cloud based drug discovery platform.

By region, the global cloud based drug discovery platform market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. North America is anticipated to lead the global cloud based drug discovery platform market on the account of easy availability of cloud platforms which support different enterprises to collect real-time data across the globe. These types of platforms deliver better access to data during the research and development process. Pharmaceutical and biotech vendors in North America are developing new technologies in order to enhancing drug development process by deploying cloud platforms.

Buy Now- https://www.kennethresearch.com/report-purchase-id-10076261

Market Segmentation

Our in-depth analysis segmented the global cloud based drug discovery platform market in the following segments:

By Type

PaaS (Platform as a Service)
SaaS (Software as a Service)
IaaS (Infrastructure as a Service)
By Application

Pharmaceutical Companies
Hospitals
Biotech Vendors
Contract Research Organizations
By Region

The global cloud based drug discovery platform market is further classified on the basis of region as follows:

North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis.

Growth Drivers and Challenges

The various growth drivers associated with the global cloud based drug discovery market are increasing implementation of cloud-based platforms in the healthcare industry in order to improve research efficiency. The various developing technology such as machine learning and artificial intelligence enable better discovery and formulation of drug around the globe. The various regional healthcare companies are collaborating with the international healthcare market players in order to adopt cloud based technologies which will enable better discovery and identification of diseases. Cloud-based drug discovery platform can be accessed by many devices such as computers, notebook, and mobiles.

Various issues related to correlation of applications with devices are expected to hamper the market of cloud based drug discovery platform.

Key Players

IBM Corp,
Accenture PLC
BioXcel Corporation
Cloud Pharmaceuticals, Inc.
WuXi AppTec (Shanghai) Co., Ltd.
Dassault Systemes
BIOVIA Ltd.

Read More- https://www.kennethresearch.com/report-details/cloud-based-drug-discovery-platform-market/10076261

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

1412 Broadway,
21st Floor Suite MA111,
New York, NY 10018

Name:David
Email:sales@kennethresearch.com
Phone: +1 313 462 0609

This release was published on openPR.